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Summary
MLL fusion proteins are leukemogenic, but their mechanism is unclear. Induced dimerization of a truncated MLL immortal-
izes bone marrow and imposes a reversible block on myeloid differentiation associated with upregulation of Hox a7, a9,
and Meis1. Both dimerized MLL and exon-duplicated MLL are potent transcriptional activators, suggesting a link between
dimerization and partial tandem duplication of DNA binding domains of MLL. Dimerized MLL binds with higher affinity than
undimerized MLL to a CpG island within the Hox a9 locus. However, MLL-AF9 is not dimerized in vivo. The data support
a model in which either MLL dimerization/exon duplication or fusion to a transcriptional activator results in Hox gene
upregulation and ultimately transformation.
Introduction terminal fragment MLLN is a 300 kDa protein that contains DNA
binding motifs including three AT hooks and a DNA methyltrans-
ferase homology region that targets MLL to particular chromo-Rearrangements of the mixed lineage leukemia gene MLL, the
human homolog of Drosophila trithorax, are associated with somal sites. The C-terminal region of MLLN contains multiple
cysteine-rich zinc finger domains (termed PHD for plant homeo-aggressive lymphoid and myeloid leukemias. The most common
of these are the t(4;11),(MLL-AF4) and t(11;19),(MLL-ENL), domains) that flank a bromodomain region. These sequences
by themselves have repressive effects on transcription. Becausetranslocations that are strongly associated with acute lympho-
blastic leukemias in infants. MLL rearrangements are also one MLLN noncovalently associates with MLLC, which has potent
transcriptional activating activity, MLL has net activating effectsof the most common genetic alterations in acute myelogenous
leukemia, occurring in about 10% of cases, particularly those on transcription. This is likely the result of recruitment of the
known histone acetyltransferase CBP (Ernst et al., 2001), recruit-with monocytic or myelomonocytic differentiation. These leuke-
mias result from a different set of translocations, including the ment of the SWI/SNF chromatin remodeling complex (Rozen-
blatt-Rosen et al., 1998), and intrinsic lysine 4 methyltransferaset(9;11) and t(6;11), which express MLL-AF9 and MLL-AF6, re-
spectively (Sorensen et al., 1994; Downing and Look, 1996; activity of the highly conserved MLL C-terminal SET domain
(Milne et al., 2002; Nakamura et al., 2002).DiMartino and Cleary, 1999). In addition, internal tandem dupli-
cations of MLL occur in about 10% of cytogenetically normal The best understood targets of MLL are the clustered ho-
meobox or Hox genes (Yu et al., 1998). Studies of Mll knockoutAML cases, and are associated with a worse prognosis (Caligiuri
et al., 1998; Dohner et al., 2002). In all, more than 40 different mice showed that MLL positively regulates expression of the
clustered Hox genes during development (Yu et al., 1995). Re-translocations have been identified, making MLL rearrange-
ments one of the most common genetic alterations in human cently, we and others have shown that MLL activates Hox gene
transcription by binding directly to Hox promoters and promot-leukemia.
MLL is a large protein (3968 aa) that is proteolytically cleaved ing histone acetylation and H3 lysine 4 methylation (Milne et
al., 2002; Nakamura et al., 2002). MLL is required for normal Hoxinto two fragments before entering the nucleus (Nakamura et
al., 2002; Yokoyama et al., 2002; Hsieh et al., 2003). The amino- gene expression and proliferation of hematopoietic progenitors,
S I G N I F I C A N C E
MLL is truncated and fused to one of over 40 different translocation partners in aggressive human acute lymphoid and myeloid
leukemias. The occurrence of some MLL translocation partners known to exist as dimers or tetramers in vivo suggests that one role
of these partners may be to dimerize MLL. Our results show that MLL dimers immortalize cells, block myeloid differentiation, upregulate
Hox a7, a9, and Meis1, and bind with higher affinity to their targets. However, not all MLL fusions dimerize in vivo. These findings may
explain differences in efficiency of transformation by MLL fusion proteins and have important implications for the development of
MLL-directed therapy.
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particularly of myelomonocytic lineage (Hess et al., 1997). This
link between MLL, Hox gene regulation, and hematopoiesis is
of particular importance because of the growing experimental
evidence implicating changes in Hox gene expression with ex-
perimental and human leukemias (Kroon et al., 1998; Kawagoe
et al., 1999; Buske and Humphries, 2000; Armstrong et al.,
2002; Fujino et al., 2001; Rozovskaia et al., 2001; Drabkin et
al., 2002).
While some insights into the function of wild-type MLL have
been obtained, the role of MLL fusion proteins in transformation
is poorly understood. Transformation by MLL requires fusion to
a translocation partner, indicating that MLL-mediated transfor-
mation is not simply a loss of function mechanism. Transloca-
tions involving MLL cluster in exons 5 through 8 and consistently
replace the PHD domain and distal domains with an in-frame
fusion to one of many translocation partners that, in general,
share little sequence homology. The other derivative product is
not required for transformation and the fusion proteins appar-
Figure 1. Dimerization of MLL-FKBP transforms murine bone marrowently do not interact with MLLC (Yokoyama et al., 2002). This
A: Methylcellulose cultures of murine bone marrow transformed by MLL-AF9large number of translocation partners that lack sequence ho-
show compact colonies characteristic of MLL fusion protein transformation.mology has made it difficult to develop a unifying theory for B: Wright Giemsa-stained cytospins of MLL-AF9 transformed cells show my-
how rearranged forms of MLL are leukemogenic. eloblastic morphology.
C: Immunophenotypic analysis of MLL-AF9 transformed cells shows expres-Many commonly occurring MLL translocation partners are
sion of myeloid (Mac-1, Gr-1) and hematopoietic progenitor markers (c-Kit),transcription factors, including AF4, AF9, and ENL that activate
but not the erythroid lineage marker, Ter119.transcription when tethered to heterologous promoters. This D: MLL-FKBP-transduced bone marrow cultured in the presence of 50 nM
suggested a simple mechanism of target gene activation by dimerizer shows compact colonies similar to MLL-AF9-transformed cells.
When individual colonies of MLL-FKBP were picked and replated, only colo-fusion of transcriptional activation domains to MLL, a finding
nies with compact morphology gave rise to IL3 dependent cell lines.supported by reports that VP-16 fused to MLL is also trans-
E: MLL-FKBP transformed cells were myeloblasts similar to MLL-AF9 trans-forming (So and Cleary, 2003; Zeisig et al., 2003). In rare cases
formed cells and had a similar immunophenotype with Gr-1, Mac-1 and
of therapy-related leukemias, MLL is fused to CBP or the closely c-Kit expression (F).
related protein p300, raising the possibility that recruitment of
histone acetyltransferase (HAT) activity plays a role in MLL-
mediated leukemogenesis (Lavau et al., 2000).
However, not all MLL translocation partners appear to be Dimerized MLL strikingly resembles the commonly oc-
transcriptional activators (Ayton and Cleary 2001; Strehl et al., curring form of MLL with internal tandem duplications of the AT
2003). Some are cytoplasmic proteins that are unlikely to have hooks and DNA methyltransferase homology regions. If dimer-
a nuclear function. The presence of self-association motifs in ization doubles the number of DNA binding domains and in-
some MLL translocation partners has prompted several investi- creases the binding affinity or changes the target specificity of
gators to propose that dimerization of truncated MLL may be MLL, then this might explain how a subset of MLL fusions cause
transforming (Prasad et al., 1994; Chaplin et al., 1995; Dobson leukemia. Determining whether dimerization of truncated MLL
et al., 1999; Sano, 2001). There is abundant indirect evidence is required for transformation is important for the future develop-
for this mechanism. AF10 and AF17 contain leucine zipper mo- ment of targeted therapies that block this self-association.
tifs that are required for transformation (DiMartino et al., 2002),
and AF10 is a homotetramer (Linder et al., 2000). AF3p21 homo- Results
oligomerizes (Sano, 2001), and guanine monophosphate syn-
thetase is a tetramer (Pegram et al., 2000). In addition, LCX, MLL dimerization is sufficient for immortalization
SEPTING, AF1p/EPS15, EEN, and AF6 all contain -helical Therefore, we tested whether MLL dimerization was trans-
coiled-coil regions that are retained in fusion proteins (Slater et forming by constructing a pharmacologically dimerizable MLL
al., 2002; Ono et al., 2002). These coiled-coil self-association fusion protein (Amara et al., 1997) within an MSCV-based ret-
domains resemble the rod-like domains that mediate dimeriza- roviral vector (Hawley et al., 1994). We fused a modified form
tion of myosin chains and therefore are also likely to self-associ- of the 12 kD FK506 binding protein (FKBP12) in-frame to MLL
ate. Perhaps the most compelling experimental evidence for a in exon 7, a common site of translocation breakpoints, to gener-
dimerization model is the finding that MLL-lacZ knockin mice ate the construct MSCV-MLL-FKBP. When expressed, this
developed both lymphoid and myeloid leukemias, albeit with a MLL-FKBP fusion protein dimerizes only in the presence of the
long latency period (Dobson et al., 1999). -galactosidase has dimerizer AP20187. Murine bone marrow was transduced with
no known transcriptional activity, nor is it homologous to any MLL-FKBP retrovirus, a retrovirus expressing MLL-AF9, an MLL
known MLL translocation partner. However, in its active form, fusion protein associated with acute myeloid leukemias, or a
the enzyme is a tetramer in solution (Appel et al., 1965; Jacobson control virus expressing only NeoR (MSCV Neo). Retroviral trans-
et al., 1994), implying that the primary role of the translocation duction of 5-FU-primed bone marrow with MLL-AF9 readily
transformed the cells to generate myeloblastic cell lines capablepartner in these experimental leukemias is to oligomerize MLL.
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Figure 2. MLL-FKBP dimerization promotes proliferation and reversibly blocks myeloid differentiation
A: Colony counts on 103 MLL-FKBP cells plated in methylcellulose with added growth factors in the presence and absence of dimerizer. Only cells plated
in the presence of dimerizer gave rise to compact colonies, which could be maintained in IL-3 alone in liquid culture.
B: MLL-FKBP cells growing in the presence of dimerizer and IL-3 or dimerizer and IL-3  SCF were washed in complete medium and replated in the presence
or absence of 50 nM dimerizer and IL3 or IL3  SCF. Viable and dead cells were counted using Trypan blue exclusion at 24, 48, 72, and 96 hr. Upon dimerizer
withdrawal, cells grown either in the presence of IL-3 alone or IL-3  SCF fail to proliferate, while cells grown in the presence of dimerizer grow robustly.
C and D: Cell cycle analysis of MLL-FKBP-transformed cells. Cells grown in the presence of dimerizer and IL-3  SCF were washed and replated in complete
medium with IL-3  SCF in the presence or absence of dimerizer. Cells were harvested 48 hr later and labeled with propidium iodide, and cell cycle analysis
was performed. Cells growing in the presence of dimerizer (C) had an S phase fraction of 46% (similar to MLL-AF9-transformed cells; data not shown), while
removal of dimerizer (D) resulted in a decreased S phase fraction (15%).
E and F: Morphology of MLL-FKBP-transformed cells grown in the presence of dimerizer and 20 days after dimerizer withdrawal. Wright-Giemsa staining of
cytospins reveals myeloblast morphology in cells grown in the continuous presence of dimerizer (E); after dimerizer withdrawal, MLL-FKBP cells (F) differentiate
into neutrophils and macrophages, reflecting release from a block in myeloid differentiation.
of growing in liquid culture in IL-3 only. These cells formed both IL-3 and SCF factor for growth initially in liquid culture.
Ultimately, the MLL-FKBP-transduced cells proliferated as fastcompact colonies in methylcellulose replating assays with re-
plating properties similar to those reported for the closely related as the MLL-AF9 transduced cells and could be weaned to IL-3
alone. MLL-AF9 gave rise to oligoclonal populations of integ-MLL-ENL (Lavau et al., 1997). MLL-AF9 cells had myeloblastic
morphology, and immunophenotyping revealed expression of rants, implying a high efficiency of transformation, whereas
MLL-FKBP (Figures 4A and 4B) gave rise to monoclonal integra-the myeloid markers Gr-1 and Mac-1 as well as c-Kit; the ery-
throid marker Ter-119 was not expressed (Figure 1C). tions, implying a lower efficiency.
MLL-AF9 cells, when injected into busulfan-treated, immu-Transduction of MLL-FKBP in the absence of dimerizer did
not immortalize cells. Although the number of primary colonies nosuppressed mice either intravenously or intraperitoneally, re-
sulted in acute myeloid leukemias in all recipients by 60 days.was similar initially, in five separate experiments, the transduced
cells died after three to four replatings in methylcellulose, and no Testing the ability of MLL-FKBP cells to cause leukemia in vivo
presented challenges because of the short in vivo half-life andcell lines could be established (data not shown). Only compact
colonies from cells grown in the presence of dimerizer generated limited supply of dimerizer, which precluded continuously pro-
viding the drug to mice.multiple myeloblastic lines that could be replated and which
grew indefinitely in liquid culture. Dimerizer was required from The transformation imposed by MLL-FKBP was reversible.
Withdrawal of dimerizer resulted in a loss in further colony for-the onset of plating in methylcellulose in order to get transforma-
tion. The MLL-FKBP-transduced cells cultured in the presence mation upon replating (Figure 2A) and a rapid arrest of cell
proliferation as shown by cell counts on trypan blue stainedof 50 nM dimerizer formed compact colonies and showed my-
eloblastic cytology (Figures 1D and 1E) and an immunopheno- cells (Figure 2B). Dimerization of MLL-FKBP also stimulates S
phase progression. Propidium iodide cell cycle analysis (Figurestype (Figures 1C and 1F) nearly identical to MLL-AF9 trans-
formed cells (Figures 1A and 1B). 2C and 2D) revealed that, similar to MLL-AF9 transformed cells,
the MLL-FKBP line in the presence of dimerizer showed a highDespite these similarities, some differences were noted in
the behavior of the cells immortalized by dimerization. First, proportion of cells in S phase and G2M, (44.2% and 9.5%,
respectively) whereas cells grown for 96 hr in the absence dimer-MLL-AF9 cells proliferated rapidly from the onset and required
only IL-3 for growth initially when transferred to liquid culture. In izer showed a sharp reduction of cells in S phase (15.7%).
Cells retained myeloblast morphology at 96 hr after dimerizercontrast, MLL-FKBP-transduced cells grew slowly and required
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withdrawal; however, over a period of 21 days, the cells differen-
tiated completely into a mixed population of predominantly mac-
rophages with admixed neutrophils (Figures 2E and 2F). These
results suggest that differentiation blockade is a fundamental
mechanism of immortalization by all MLL fusion proteins
(Schreiner et al., 2001, B. Zeisig et al., submitted).
Dimerization of MLL converts it into
a transcriptional transactivator
Naturally occurring MLL fusion proteins such MLL-AF4 and
MLL-AF9, but not truncated MLL, are potent transcriptional
coactivators that activate transcription of promoters containing
MYC E boxes as well as Hox promoters, which also contain
E boxes (Schreiner et al., 1999; Galoian et al., 2000; J.L.H.,
unpublished data). To determine if dimerization of amino-termi-
nal MLL affects coactivator activity, the MLL-FKBP expression
construct (Figure 3A) was transfected into CHO cells along with
the Myc-Luc firefly luciferase reporter, and a CMV immediate
early region regulated Renilla luciferase reporter as a control
for dual luciferase reporter assays. Analysis of transiently trans-
fected cells showed that dimerization of the fusion protein acti-
vated transcription (nearly 250-fold) in a dose-dependent man-
ner (Figure 3B). Experiments with a stably integrated reporter
gene gave similar results (Figure 3C). In contrast, addition of
dimerizer to cells transfected with an “empty” expression vector
(MSCV Neo) had no effect on transcription (Figure 3C and data
not shown).
Dimerized MLL-FKBP resembles the exon duplicated form
of MLL in that the protein complex contains increased numbers
of DNA binding motifs: two AT hook clusters and 2 DNMT
homology regions. To test the hypothesis that increased DNA
binding motifs account for the activation shown by dimerization
Figure 3. Dimerization of truncated MLL, but not the AT hooks alone, convertsMLL-FKBP, we constructed MLL-DUP (Figure 3A) and tested it it into a potent transcriptional activator
in transient and stable luciferase assays as above. Remarkably,
A: Schematic of MSCV-based constructs used for transfections, including
MLL-DUP had potent transactivating activity equivalent to that the naturally occurring translocation partner MLL-AF9,MLL-FKBP, which con-
of the dimerized MLL-FKBP in both assays, suggesting that tains a cDNA encoding the FKBP12 protein fused to MLL at the PflM1 site
within exon 7, a common site for translocation breakpoints. AT-FKBP containsduplication of DNA binding elements in MLL contributes to tran-
sequences C-terminal to the 3 AT hook motifs of MLL fused in frame toscriptional transactivation (Figure 3C).
FKBP12. MLL-DUP contains the amino-terminal sequences of MLL spanning
the AT hooks and DNMT region fused to the derivative MLL at the PflM1 site.
MLL dimerization upregulates expression B: For transient transfections, cDNAs for the MLL-AF9 fusion protein were
transfected in triplicate into CHO cells along with a Myc E box HSV TKof endogenous Hox genes and Meis 1
luciferase reporter and a CMV-driven Renilla luciferase control plasmid. TheNormally, the A cluster Hox genes, including Hox a7 and a9
expression of firefly and Renilla luciferase activity was measured using theand the Hox cofactor Meis 1, are only expressed in cKit
dual luciferase reporter assay. Results are expressed as a ratio of normalized
Thy1loLin1/loSca11rhodamine 123Rhlo hematopoietic stem firefly luciferase activity to the activity of cells transfected with an MSCV
cells (HSC), and then their expression is rapidly downregulated neomycin control vector. In the presence of the dimerizer AP20187, cells
transfected with MLL-FKBP showed strong dose-dependent transactivationin more differentiated multipotential, common lymphoid, and
of the Myc E box HSV TK reporter (bottom axis shows nM concentration ofmyeloid progenitors (Park et al., 2002; Pineault et al., 2002;
AP20187 in tissue culture medium). Dimerization of the MLL AT hooks aloneAkashi et al., 2003). However, MLL-FKBP and MLL-AF9 trans- did not transactivate.
formed cells showed persistent expression of Hox a7 and Hox C: For stable transfections, Sca1 linearized expression plasmids described
above were transfected in triplicate into CHO cells along with linearizeda9 as well as the Hox cofactor Meis 1. These findings were
PGK Hygro and Renilla luciferase control plasmid, and hygromycin-resistantidentical to the pattern of expression seen in human acute
cells were harvested for luciferase assay approximately three weeks later.lymphoid and myeloid leukemias with MLL rearrangements (Ro-
Cells transfected with FKBP showed dose-dependent increases in expression
zovskaia et al., 2001; Armstrong et al., 2002; Yeoh et al., 2002). from the stably integrated reporter construct. No transactivation was seen
We then assessed whether Hox a7, a9, and Meis 1 are directly in the Neo control. Remarkably, the exon duplicated form of MLL also
showed strong transactivation. Naturally occurring MLL fusion proteins, in-or indirectly regulated by MLL fusion proteins. Levels of MLL-
cluding MLL-AF4, MLL-AF9, and MLL-ENL typically transactivate 20- to 30-AF9 expression were measured in two MLL-AF9 transformed
fold (data not shown), a level of transactivation observed with MLL-FKBP
cells from independent experiments (Figure 4D). Cells which at approximately 50 nM of dimerizer.
expressed a higher level of MLL-AF9 also expressed increased
levels of Hox a7, a9, and Meis 1.
To more directly test the link between MLL fusion protein
activity and Hox gene expression, we plated MLL-FKBP-trans-
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that transcription of these targets is dependent on dimerization,
but do not show if the MLL-FKBP binds directly to these targets,
or how dimerization affects binding.
Binding of amino-terminal MLL to regulatory regions
of Hox genes is enhanced by dimerization
The recent discovery that wild-type MLL binds to Hox promoters
including Hox a9 and Hox c8 (Milne et al., 2002, Nakamura et
al., 2002) suggests that MLL fusion proteins regulate Hox genes
through direct promoter binding. To directly test this hypothesis,
we used chromatin immunoprecipitation (ChIP) (Orlando, 2000)
to identify MLL fusion protein binding sites in the Hox a9 locus.
Chromatin was prepared from MLL-FKBP-immortalized cells
grown in either the presence or absence of dimerizer, and immu-
noprecipitations were performed using antibodies to either
FKBP12 or the C-terminal HA tag. A series of primers for quanti-
tative PCR to the CpG-rich coding region and sequences up-
stream of the transcriptional start site of the murine Hox a9
gene were used to detect MLL fusion protein binding (Figure
5A). In multiple experiments using both antibodies, we detected
reproducible binding of MLL-FKBP only to the CpG rich region
spanning Hox a9 exon 1 (Figures 5B and 5C). This is noteworthy
because many Hox genes contain CpG islands within their first
exons and also because of the recent finding that the DNMT
domain of MLL preferentially binds unmethylated CpG-rich DNAFigure 4. Expression of MLL-AF9 and dimerization of MLL-FKBP upregulate
Hox gene expression in vitro (Birke et al., 2002). The binding we observed is within
1 Kb of the MLL binding site reported in a limited analysis ofA: Southern blot of genomic DNA from MLL-AF9 and MLL-FKBP-transformed
bone marrow cells digested with Kpn I and probed with an MLL HindIII the human HOX A9 promoter (Nakamura et al., 2002).
probe, confirming the integrity of the proviral DNA in both lines. The upper Wild-type MLL contains self-association motifs in the PHD
band represents wild-type mouse embryonic fibroblasts (MEF), which are
fingers (Fair et al., 2001) and SET domain (Rozovskaia et al.,used as a probe control.
2000), suggesting that MLL normally functions as a dimer orB: Southern blot showing multiple viral integration sites in an MLL-AF9 line
(black arrowheads) but only a single integration site in the MLL-FKBP line oligomer. These domains are deleted in MLL fusion proteins,
(white arrowhead). raising the possibility that MLL dimerization and redimerization
C: Expression of constructs in various lines as assessed by RT-PCR. MLL-AF9 of the derivative MLL by the translocation partner is required
and MLL-FKBP are only expressed in bone marrow cells transformed with
for Hox promoter binding. This suggestion is supported by ourthe respective virus. Expression levels of MLL-FKBP remain constant in the
finding that exon-duplicated MLL acts as a transcriptional acti-presence () or absence () of dimerizer.
D: Levels of MLL-AF9 expression correlate with levels of Hox gene expression. vator. Although increased binding was detected in the presence
Two different MLL-AF9 transformed cell lines (MLL-AF9#3 and #6) express of dimerizer, undimerized MLL (MLL-FKBP) was still capable of
Hox a9, Hox a7, and Meis1 as quantified by real-time PCR. Relative expres-
weak binding, suggesting that MLL dimerization is not requiredsion levels of Meis1 and the Hox genes are higher in the MLL-AF9#6 line,
for binding to the Hox a9 locus (Figure 5C). The results supportwhich also correlates with higher MLL-AF9 expression levels (inset) and faster
growth rate (data not shown). the hypothesis that it is an increase in affinity of binding by
E: Endogenous Hox gene expression is upregulated by MLL-FKBP dimeriza- dimerized MLL fusions or exon-duplicated MLL, rather than a
tion. Expression of Hox a9, Hox a7, and Meis1 was quantified using real-time change in specificity, that causes transformation.
PCR in cells transformed with either MLL-AF9 or MLL-FKBP. Gene expression
is maintained in the MLL-FKBP line in the presence () of dimerizer. Removal
Is MLL fusion protein dimerization required in vivo?of dimerizer for 4 days (, 4) results in a reduction of gene expression. Within
24 hr of adding dimerizer back (, 1) both Hox a9 and Meis1 expression To test if dimerization is required for transformation, we used
return to previous levels, while Hox a7 expression is increased after 3 days -lactamase complementation to determine if intact MLL-AF9
(, 3). Levels of Hox and meis1 expression are low in a dimerizer-indepen-
was dimerized in vivo. This assay relies on the ability of twodent cell line (ind).
fragments of -lactamase to reconstitute activity when hetero-
dimerized. Coding sequences for two fragments of -lactamase
shown to complement activity when dimerized (Wehrman et al.,
2002) were cloned in-frame at the PflM1 site of MLL-FKBP orformed cells in the presence and absence of dimerizer for vari-
MLL-AF9, which introduces the lactamase fragments immedi-able lengths of time and then prepared RNA from these cultures
ately amino-terminal to the translocation partners (Figure 6). Asfor quantitative PCR analysis. MLL-FKBP-transformed cells ex-
a positive control, the intact -lactamase was cloned into apressed levels of Hox a7, Hox a9, and Meis1 (Figure 4E) compa-
control vector pBla in place of the MLL sequences. The variousrable to MLL-AF9 transformed cells. Upon dimerizer withdrawal,
constructs were transfected into 293 cells, which were loadedthe levels of Hox a7, Hox a9, and Meis1 expression fell dramati-
with the CCF2/AM substrate at either 48 or 72 hr. -lactamasecally (Figure 4E). Importantly, readdition of dimerizer to cells
activity was detected by cleavage of the fluorogenic substratedeprived of dimerizer for four days resulted in prompt upregula-
CCF2/AM. When excited by UV laser at 409 nm, the emissiontion of Hox a7, Hox a9, and Meis 1 expression, with a slight
decrease in Meis1 expression at day 3. These results establish of the dye CCF2/AM at 520 nM is shifted to 447 nM when
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Figure 5. Detection of MLL-FKBP binding sites in vivo using chromatin immunoprecipitation
A: Schematic of the Hox A9 locus. Distances in kb are marked below the line. Two different transcriptional start sites are marked by arrows. Yellow boxes
below the line denote AT-rich sequences, and black boxes below the line denote putative CpG islands. The TATA box is the site of a previously characterized
MLL binding site (Nakamura et al., 2002). Positions of Taqman primer/probe sets used to survey for MLL-FKBP binding sites are shown above the line in red.
The exon 1 primer/probe set is the only site that gave a consistent positive signal.
B: ChIP analysis of MLL-FKBP cells grown in the presence () or absence () of dimerizer using an antibody to the C-terminal hemagglutinin tag (HA).
Shown are PCR results detecting binding at the position of Hox A9 exon 1. Increased binding is seen in the presence of dimerizer (HA,).
C: Quantification of ChIP results from B as a percentage of input chromatin using the Taqman primer/probe set exon 1. Increased binding is seen in the
presence of dimerizer (HA,), but weak residual binding is still seen in the absence of dimerizer (HA, ). Only background signal is detected in the no
antibody control or at the  Actin locus.
cleaved by enzymatically active -lactamase. Cleaved CCF2/ izer. In contrast, a significant shift to 447 nm emission was seen
in MLL-FKBP - and-expressing cells cultured in the presenceAM would only be present if the two complementary halves of
of dimerizer, indicating a reconstitution of -lactamase activitythe enzyme were brought into close proximity by dimerization.
reflecting dimerization of the fusion proteins molecules in vivo.The results are shown in Figure 7. Intact CCF/AM2 emits at 520
No distinct population of cells showing bright 447 nm emissionnm (green, Figure 7C), while after cleavage it emits at 447 nm
was observed in cells expressing MLL-AF9  or  or both,(blue, Figure 7D). Transfection of pBla resulted in a substantial
indicating that this fusion protein is not dimerized in vivo. Con-shift to 447 nm emission, indicating reconstituted -lactamase
sistent with this observation, immunoprecipitation studies inactivity. An insignificant population of cells emitting at 447 nm
cells cotransfected with epitope tagged AF9 did not show evi-was seen in cells singly transfected with either MLL-FKBP  or
dence of self-interaction (data not shown). These data suggest either with or without dimerizer (data not shown) or in cells
that MLL-AF9 is not dimerized in vivo and that dimerization ofcotransfected with MLL-FKBP  and  in the absence of dimer-
MLL fusions is not obligatory for transformation.
Discussion
Multiple mechanisms for MLL fusion
protein-mediated transformation
The molecular mechanisms by which MLL translocations trans-
form are unclear. Previously, Ayton and Cleary suggested that
alternative paths exist for MLL fusion protein-mediated transfor-
mation (Ayton and Cleary, 2001). One pathway involves com-
mon translocation partners that are nuclear proteins with tran-
Figure 6. Constructs used in -lactamase complementation assay scriptional activating activity such as MLL-AF4, MLL-AF9, and
Schematic of the MLL-AF9  and  and MLL-FKBP  and  cDNAs under the MLL-ENL. Balanced translocations involving MLL have two mo-
transcriptional control of a CMV/ actin promoter used for -lactamase lecular consequences. They delete the sequences involved incomplementation. The 197 or 198 portions of the -lactamase gene were
transcriptional activation through histone methylation (Milne etinserted in frame into MLL at the PflM1 site as described in the Experimental
Procedures (GS  glycine/serine-rich linker). al., 2002; Nakamura et al., 2002), but also delete the PHD fingers,
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Figure 7. Detection of MLL dimerization in vivo by -lactamase complementation
A: Forward versus side scatter of transfected cells.
B: Histogram of blue (CCF2/AM cleaved by -lactamase) versus green (intact, uncleaved CCF2/AM) fluorescence intensity.
C shows intact CCF2/AM fluorescence, while D shows blue fluorescence intensity. The percent of cells (P2/P1) showing blue fluorescence (cleaved CCF2/
AM) indicates that cells transfected with both MLL-FKBP and MLL-FKBP constructs in the presence of dimerizer reconstitute -lactamase activity, while
in the absence of dimerizer, there is no cleavage of the CCF2/AM substrate, indicating that dimerization of MLL-FKBP is required for its activity. MLL-AF9
transfected cells do not demonstrate -lactamase activity, nor do cells cotransfected with the complementary  and  MLL-AF9 constructs.
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which may play a role in recruiting corepressors (Fair et al., FKBP had different potencies for transformation, the proteins
produced comparable levels of Hox a7, Hox a9, and Meis12001; Schultz et al., 2001). It is noteworthy in this regard that
in some T-ALLs, the only MLL alteration is that exon 8 is deleted, expression. This suggests that the two differ in their potency
through deregulation of target genes outside of the clusteredresulting in deletion of 33 amino acids of the first PHD finger
(Chervinsky et al., 1995; Ayton and Cleary, 2001). Additionally, Hox genes. A second surprising result was that with increasing
passage, the conditionally transformed MLL rapidly becamestrongly transforming translocation partners such as ENL and
AF9 likely upregulate Hox expression by recruiting transcrip- dimerizer-independent (Figure 4E). Although Hox and Meis1 ex-
pression was still dependent on dimerizer, the cells continuedtional coactivators. ENL, for example, has recently been shown
to be part of a SWI/SNF chromatin remodeling complex (Nie et to grow in its absence, suggesting that additional genetic hits
had occurred that rendered these cells less dependent on Hoxal., 2003). Apparently, dimerization of this class of MLL fusion
proteins is not required for target binding, perhaps because the proteins. The conditionally transformed cells therefore provide a
unique model system for studying the acquisition of cooperatingtranslocation partner either provides domains or interacts with
proteins that contribute to binding. In the case of ENL, these oncogenes in MLL-associated leukemia. Finally, these findings
will have important implications for the development of therapymight be the AT hook motifs in BRG1 associated with the ENL
complex that have been shown to bind DNA (Bourachot et al., targeting either MLL gain-of-function activity or downstream
Hox protein activity.1999).
The second pathway is associated with less common trans-
Experimental procedureslocation partners, particularly cytoplasmic proteins, that tend
to be associated with long latencies in experimental animal
Cell culture and transfection
models and that are seen more commonly in adult or secondary CHO-AA8-Tet off cells (BD Biosciences Clontech, Palo Alto, CA) and 293
leukemias. An increasing number of these rare cytoplasmic MLL human embryonic kidney cells were grown in Dulbecco’s modified eagle
translocation partners, including LASP, FBP17, ABI1, and medium (DMEM) supplemented with 10% fetal bovine serum (FBS), l-gluta-
mine, and penicillin/streptomycin (all from Gibco, Grand Island, NY).GRAF, have been shown to be incapable of transforming in
in vitro progenitor assays (Strehl et al., 2003). Dimerized MLL
Reporter and expression plasmidsappears to be a good model for the latter group, as it inefficiently
A Mercury reporter plasmid (Clontech) containing the HSV minimal promoter
immortalizes bone marrow cells, presumably because it requires and multimerized copies of MYC E box binding sites was used as an MLL-
additional genetic events for complete transformation. responsive reporter for cotransfection assays. RL-CMV, used as a control
The mechanism by which dimerization of MLL results in in all transfections, expresses Renilla luciferase under the control of the CMV
immediate-early promoter (Promega, Madison, WI). The MSCV Neo retroviraltranscriptional activation is less clear. The finding that partially
vector used as a control has been previously reported (Hawley et al., 1994).duplicated forms of MLL also had potent coactivator activity
The plasmid pC4Fv1E containing the 12 Kd FK506 binding protein (FKBP12)(Figure 3C) suggests that duplication of potential DNA binding
fused to a carboxy terminus hemagglutinin (HA) tag (Ariad Pharmaceuticals,elements such as the AT hooks or DNA methyltransferase ho-
Cambridge, MA) was digested with PflMI/XhoI to release the FKBP12 frag-
mology region may play an important role in transformation. ment. MSCV MLL-FKBP and MSCV MLL-AF9 were created from MSCVMLL-
The duplicated DNA binding domains might interfere with core- ENL by cloning the 377 bp PflMI/XhoI FKBP fragment into exon 7 or the
270 bp AF9 BamH1/XhoI fragment into exon 8 of MLL in place of the ENLpressor binding to CpG repeats, or AT hook-mediated DNA
insert. Both plasmids contained neomycin resistance genes. The -lactamase-bending could facilitate transcription factor binding further up-
containing constructs were constructed by PCR amplication of the 197stream, or increased affinity might stabilize interactions with
-lactamase fragment from FKBP197, and the 198  lactamase fragmentcoactivators. Determining whether MLL fusions outcompete the
from FKBP198 with primers that generate PflM1 sites flanking the insert
unrearranged form of MLL for target binding or alter corepressor and in-frame with the 5 PflM1 site in MLL (Wehrman et al., 2002). Following
or coactivator recruitment will be important for developing a subcloning, the inserts were recloned in the sense orientation into the PflM1
coherent model for how internal tandem duplications or dimer- site of the CMV/ actin promoter expression vector pCXN to generate pF-
MLL-FKBP and pF-MLL-AF9, and constructs were confirmed by sequencingization of MLL activate transcription.
across the insert.Regardless of the mechanism for transcriptional activation,
increasing data suggest that Hox a7, Hox a9, and Meis1 are
Transfections
pivotal targets for MLL fusion protein-mediated transformation Cells were seeded at a density of 104 cells per well of 12-well cluster dishes
(Li et al., 1999; Thorsteinsdottir et al., 2001, 2002). These genes and were transfected 24 hr later using CaPO4 precipitation. For a typical
are consistently expressed in leukemias with MLL rearrangements transfection, 500 ng firefly luciferase reporter, 500 ng of expression vector,
(Rozovskaia et al., 2001; Armstrong et al., 2002; Yeoh et al., and 500 ng Renilla luciferase reporter were transfected per well. Cells were
harvested for dual luciferase assay (Promega) 48 hr after transfection and2002), and abundant experimental data suggest this combina-
luciferase activity quantified using a Moonlights 3010 illuminometer (Harlin-tion is transforming. Hox a7 and Hox a9 are commonly overex-
gen, San Diego, CA). All values were normalized to Renilla luciferase activity,pressed as a result of retroviral integration in BXH2 leukemias
and fold activation overexpression vector alone was expressed as the aver-
(Moskow et al., 1995; Nakamura et al., 1996), and this is almost age of three separate transfections. For dimerization experiments, AP20187
always accompanied by overexpression of Meis1. Coexpres- (Ariad) was reconstituted as a 1 mM stock in 100% ethanol and was diluted
sion of Hox a9 and Meis1 is sufficient to block G-CSF-induced into media and added to cells immediately following transfection so that all
cultures contained identical amounts of ethanol (0.05%).differentiation and permit stem cell factor-induced proliferation.
Cotransduction of Hox a9 and Meis1 rapidly accelerates leuke-
Retrovirus production, transduction of murine primary bonemia development in transplanted mice (Kroon et al., 1998). Most
marrow cells, and establishment of cell linescompellingly, expression of Hox a9 and Meis1 can completely
High titer retrovirus was produced by calcium phosphate transfection of the
replace the block in myeloid differentiation imposed by a condi- GP isotropic packaging cell line with MSCV-MLL-AF9, MSCV-MLL-FKBP,
tional form of MLL-ENL (B. Zeisig et al., submitted). or MSCV Neo. Virus was harvested 48–72 hr after transfection, filtered, and
stored at80	C. Titering on NIH 3T3 cells (Pear et al., 1993) yielded viral titersIt is therefore surprising that although MLL-AF9 and MLL-
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in the range of 106 to 107 colony forming units/ml. Retroviral transduction of the quantification method of Frank et al. (2001). Primer/probe sequences
are available upon request.primary bone marrow cells was performed as previously described (Lavau
et al., 1997). Briefly, 6-week-old female C57Bl/6 mice (Taconic Farms, Ger-
-lactamase assaysmantown, NY) were primed with intraperitoneal injections of 150 mg/kg
293 cells were split 24 hr prior to transfection and plated at 75,000 cells/of 5-fluorouracil. Four days later, bone marrow cells (BMCs) enriched in
well in 12 well plates. Cells were transiently transfected with 4 
g of reporternoncycling progenitors were harvested from the femurs and tibiae of mice
DNA using Fugene reagent (Roche Diagnostics, Indianapolis IN) accordingand activated overnight in Iscove’s modified Dulbecco’s medium (IMDM)
to the manufacturer’s directions. Forty-eight to 72 hr later, medium with orcontaining 15% FBS (Stem Cell Technologies, Vancouver, BC, Canada)
without 500 nM dimerizer was removed and cells were washed with serum-interleukin 3 (IL-3), interleukin 6 (IL-6), and stem cell factor (SCF) (all from
free medium, and 1 ml serum-free medium with or without dimerizer wasR&D Systems, Minneapolis, MN). BMCs were transduced by spinoculation
added to each well. To assay -lactamase activity, the CCF2/AM substrateon two consecutive days with MLL-AF9, MLL-FKBP, and MSCV Neo retrovi-
(PanVera, Madison, WI) was added to each well at a final concentrationral supernatants in the presence of polybrene. 104 and 105 cells/ml were
of 1 
M. Cells were loaded for 1 hr at room temperature according tocultured in duplicate in MethoCult M3234 methylcellulose medium (Stem
manufacturer’s directions, mechanically dissociated, washed, and resus-Cell Technologies) in IMDM, 15% FBS, IL-3, IL-6, and granulocyte-monocyte
pended in PBS for analysis on a FACS/Diva (Becton Dickinson) with filterscolony stimulating factor (R&D Systems), all at 10 ng/ml, and SCF at 100
to detect excitation at 407 nm and emission at 450/20 nm (blue) and 550/ng/ml. G418 (Gibco) was added to a final concentration of 1 mg/ml. Dimerizer
30 nm (green).was added to a final concentration of 50 nM to cells transduced with MLL-
FKBP and was replaced every 3 days. Cell growth and colony morphology
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